pharmacogenomics testing is the testing of certain genes to detect gene variants that determine how individuals may react to specific medications. With pharmacogenomics testing insight, healthcare providers may reduce the need for “trial-and-error” dosing and can substantially reduce the risk associated with Adverse Drug Events (ADEs).

Clinically actionable genotypes among 10,000 patients with preemptive pharmacogenomic testing – PubMed (nih.gov)

FlexHealth currently offers pharmacogenomics (PG) testing that identifies gene variants that influence drug metabolism and efficacy. The FDA has updated the label of more than 200 drugs to include pharmacogenomics information and the breadth of coverage continues to grow.

Examples of genes targeted by the FlexHealth pharmacogenomics (PG) Panel include:
• CYP2D6 is the best-studied drug-metabolizing enzyme and affects 25% of all prescription drugs.
• CYP2C9 acts on 15% of drugs in clinical us
• CYP2C19 acts on 15% of drugs in clinical use

You and your healthcare provider will receive a comprehensive personalized genetic profile report that provides information on drug-drug and FDA approved drug-gene interactions.

Pharmaceutical companies routinely use pharmacogenomic (PGx) tests in clinical trials to identify and exclude people for whom the drug will be dangerous or ineffective or to better understand the efficacy of their clinical drug candidates. Medical centers around the world are using PGx tests on patients to avoid serious drug side effects, reduce trial-and-error, and achieve more efficacious prescribing. PGx testing is a crucial part of precision medicine, and with our patient/provider-friendly report, you can have a more informed discussion about your medication program.

Commercial insurance coverage is very limited but varies by plan and provider. They may cover PGx testing in some diagnostic situations including adverse drug reactions or lack of response to medication, pain management, cancer management, and management of many co-morbid conditions.

GINA is a U.S. federal law that protects against genetic discrimination in the workplace and through one’s health insurance. It also safeguards individual and family privacy of genetic information. With new advances in science, technology, and data management, GINA plays a vital role in establishing a baseline of protection for all Americans against discrimination. See links below for additional details.

https://www.eeoc.gov/statutes/genetic-information-nondiscrimination-act-2008

https://www.genome.gov/about-genomics/policy-issues/Genetic-Discrimination

FlexHealth is committed to protecting your information. Our Privacy Notice described how medical information about you may be used and disclosed and how you can get access to this information. Read the HIPAA Notification